Clinical Study

A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease

Table 1

Baseline characteristics according to the randomized groups. Median (25, 75 percentiles) or number is given.

CharacteristicsSaxagliptinPlacebo

Age (years)68.5 (63.0, 73.0)64.0 (58.5, 67.5)
Number (female)6 (0)6 (1)
Years of diabetes7.8 ± 4.49.2 ± 3.6
Years of CAD6 (1, 15)2 (1, 7)
Hypertension (n)56
Previous AMI (n)33
Current smoker (n)21
SBP (mmHg)128 (121, 144)133 (123, 145)
DBP (mmHg)75 (68, 79)74 (69, 80)
Waist circumference (cm)103 (90, 117)105 (94, 110)
BMI (kg/m2)28.1 (25.1, 32.3)28.6 (24.7, 29.0)

Medication (n)

Glimepiride21
Metformin56
Platelet inhibitors45
ACE-inhibitors or ARBs46
Betablocker56
Statin66
Diuretic31

AMI: acute myocardial infarction; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker.